|
| | AVL-292 Basic information |
| Product Name: | AVL-292 | | Synonyms: | AVL-292;LMK-435;N-[3-[[5-Fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide;2-Propenamide, N-[3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-;CC-292 (AVL-292);CC-292,LMK-435;N-[3-[[5-Fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide AVL292;CC-292 | | CAS: | 1202757-89-8 | | MF: | C22H22FN5O3 | | MW: | 423.44 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1202757-89-8.mol |  |
| | AVL-292 Chemical Properties |
| density | 1.322±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | ≥21.15 mg/mL in DMSO; insoluble in H2O; ≥4.9 mg/mL in EtOH with gentle warming and ultrasonic | | form | solid | | pka | 13.22±0.70(Predicted) | | CAS DataBase Reference | 1202757-89-8 |
| | AVL-292 Usage And Synthesis |
| Uses | Bruton’s tyrosine kinase (BTK) is a non-receptor tyrosine kinase involved in signal transduction pathways regulating the proliferation, activation, and differentiation of B cells. AVL-292 is an orally available, selective, and irreversible inhibitor of BTK (IC50 = 0.5 nM in vitro in B cell lymphoma cell lines) that targets and covalently binds to BTK at cysteine-481, thereby preventing its activity. AVL-292 has been shown to inhibit osteoclast function and to reduce osteoclast-stimulated proliferation of multiple myeloma cells in animal models of rheumatoid arthritis and multiple sclerosis, both of which are diseases where B cells play an important role. In clinical trials, AVL-292 has demonstrated therapeutic significance in the treatment of both B cell-related cancers (e.g., non-Hodgkin’s lymphoma and B cell chronic lymphocytic leukemia) and autoimmune diseases (e.g., rheumatoid arthritis).[Cayman Chemical] | | target | Btk |
| | AVL-292 Preparation Products And Raw materials |
|
